Department of Bariatric and Metabolic Surgery, Chelsea and Westminster Hospital, Chelsea, London.
Department of Bariatric and Metabolic Surgery, Chelsea and Westminster Hospital, Chelsea, London.
Surg Obes Relat Dis. 2018 Nov;14(11):1691-1699. doi: 10.1016/j.soard.2018.07.010. Epub 2018 Aug 2.
Intragastric balloons represent an endoscopic therapy aimed at achieving weight loss by mechanical induction of satiety. Their exact role within the bariatric armamentarium remains uncertain.
Our study aimed to evaluate the use of intragastric balloon therapy alone and before definitive bariatric surgery over a 16-year period.
A large city academic bariatric center for super-obese patients.
Between January 2000 and February 2016, 207 patients underwent ORBERA intragastric balloon placement at esophagogastroduodenoscopy. Four surgeons performed the procedures, and data were entered prospectively into a dedicated bariatric database. Patients' weight loss data were measured through body mass index (BMI) and excess weight loss and recorded at each clinic review for up to 5 years (60 mo). Treatment arms included intragastric balloon alone with lifestyle therapy or intragastric balloon and definitive bariatric surgery: gastric banding, sleeve gastrectomy, or Roux-en-Y gastric bypass. An additional treatment arm of analysis included the overall results from intragastric balloon followed by stapled procedure.
One hundred twenty-nine female and 78 male patients had a mean age of 44.5 (±11.3) years and a mean BMI of 57.3 (±9.7) kg/m. Fifty-eight percent of patients suffered from type 2 diabetes. Time from initial or first balloon insertion to definitive surgical therapy ranged between 9 and 13 months. Seventy-six patients had intragastric balloon alone, and 131 had intragastric balloon followed by definitive procedure. At 60 months postoperatively the intragastric balloon alone with lifestyle changes demonstrated an excess weight loss of 9.04% and BMI drop of 3.8; intragastric balloon with gastric banding demonstrated an excess weight loss of 32.9% and BMI drop of 8.9. Intragastric balloon and definitive stapled procedure demonstrated a BMI drop of 17.6 and an excess weight loss of 52.8%. Overall, there were 3 deaths (1.4%), 2 within 10 days due to acute gastric perforation secondary to vomiting and 1 cardiac arrest at 4 weeks postoperatively.
Intragastric balloons can offer effective weight loss in selected super-obese patients within a dedicated bariatric center offering multidisciplinary support. Balloon insertion alone offers only short-term weight loss; however, when combined with definitive bariatric surgical approaches, durable weight loss outcomes can be achieved. A strategy of early and continual vigilance for side effects and a low threshold for removal should be implemented. Surgeon and unit experience with intragastric balloons can contribute to "kick starting" successful weight loss as a bridge to definitive therapy in an established bariatric surgical pathway.
胃内球囊代表了一种内镜治疗方法,通过机械诱导饱腹感来达到减肥的目的。在减肥手术中,它们的确切作用仍不确定。
我们的研究旨在评估在 16 年的时间里,单独使用胃内球囊治疗以及在确定减肥手术后使用胃内球囊治疗的效果。
一个为超级肥胖患者服务的大型城市学术减肥中心。
在 2000 年 1 月至 2016 年 2 月期间,207 名患者在食管胃十二指肠镜下接受了 ORBERA 胃内球囊置入术。四位外科医生进行了手术,数据被前瞻性地输入到专门的减肥数据库中。通过体重指数(BMI)和超重减轻来衡量患者的体重减轻数据,并在每次临床复查时记录,最长可达 5 年(60 个月)。治疗组包括单独使用胃内球囊加生活方式治疗或胃内球囊加确定性减肥手术:胃带、袖状胃切除术或 Roux-en-Y 胃旁路术。另一个分析组包括胃内球囊加吻合术的总体结果。
129 名女性和 78 名男性患者的平均年龄为 44.5(±11.3)岁,平均 BMI 为 57.3(±9.7)kg/m。58%的患者患有 2 型糖尿病。从最初或第一次球囊插入到确定性手术治疗的时间为 9 至 13 个月。76 名患者接受了胃内球囊单独治疗,131 名患者接受了胃内球囊加确定性手术治疗。术后 60 个月,单独使用胃内球囊加生活方式改变的患者超重减轻 9.04%,BMI 下降 3.8;胃内球囊加胃带的患者超重减轻 32.9%,BMI 下降 8.9。胃内球囊加确定性吻合术的患者 BMI 下降 17.6%,超重减轻 52.8%。总的来说,有 3 例死亡(1.4%),其中 2 例在术后 10 天内死于急性胃穿孔,这是由于呕吐引起的,1 例在术后 4 周发生心脏骤停。
胃内球囊可在提供多学科支持的专门减肥中心为选定的超级肥胖患者提供有效的减肥效果。单独使用球囊插入只能提供短期的体重减轻;然而,当与确定性减肥手术方法结合使用时,可以实现持久的减肥效果。应实施早期持续监测副作用和降低球囊移除阈值的策略。外科医生和单位使用胃内球囊的经验可以为在既定的减肥手术途径中作为通向确定性治疗的“启动”成功减肥做出贡献。